Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Mai 2019 06:30 ET | Quelle: Eyenovia, Inc.

Eyenovia Reports First Quarter 2019 Financial Results

NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
06. Mai 2019 08:30 ET | Quelle: Eyenovia, Inc.

Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRS-ASOA Annual Meeting

NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
01. Mai 2019 08:30 ET | Quelle: Eyenovia, Inc.

Eyenovia Announces Conference Call and Webcast for First Quarter 2019 Financial Results

NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
27. März 2019 06:30 ET | Quelle: Eyenovia, Inc.

Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results

NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
13. März 2019 08:30 ET | Quelle: Eyenovia, Inc.

Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
04. März 2019 08:30 ET | Quelle: Eyenovia, Inc.

Eyenovia to Participate in Two Upcoming Investor Conferences

NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
25. Februar 2019 08:30 ET | Quelle: Eyenovia, Inc.

Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis

MIST-2 study meets primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, good tolerability in confirmatory MIST-2 Study NEW YORK, Feb. 25, 2019 ...
13. Februar 2019 08:30 ET | Quelle: Eyenovia, Inc.

Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering

NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
06. Februar 2019 08:30 ET | Quelle: Eyenovia, Inc.

Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia

NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
30. Januar 2019 07:00 ET | Quelle: Eyenovia, Inc.

Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis

MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJet™ platform delivery technology ...

Vorherige Seite